Structural insights for producing CK2α1-specific inhibitors

被引:4
|
作者
Tsuyuguchi, Masato [1 ]
Nakaniwa, Tetsuko [2 ]
Hirasawac, Akira [3 ]
Nakanishi, Isao [4 ]
Kinoshita, Takayoshi [1 ]
机构
[1] Osaka Prefecture Univ, Grad Sch Sci, 1-1 Gakuen Cho, Sakai, Osaka 5998531, Japan
[2] Osaka Univ, Inst Prot Res, 3-2 Yamadaoka, Suita, Osaka 5650871, Japan
[3] Kyoto Univ, Grad Sch Pharmaceut Sci, Sakyo Ku, Kyoto 6068501, Japan
[4] Kindai Univ, Dept Pharmaceut Sci, Fac Pharm, 3-4-1 Kowakae, Higashiosaka, Osaka 5778502, Japan
关键词
CK2; alpha; 1; Selectivity; Binding mode; Crystal structure; Conformational change; PROTEIN-KINASE CK2; CRYSTAL-STRUCTURE; POTENT; CK2-ALPHA-2; DISCOVERY;
D O I
10.1016/j.bmcl.2019.126837
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
Casein kinase 2 catalytic subunit (CK2 alpha) is classified into two subtypes CK2 alpha 1 and CK2 alpha 2. CK2 alpha 1 is a drug discovery target, whereas CK2 alpha 2 is an off-target of CK2 alpha 1 inhibitors. High amino acid sequence homology between these subtypes hampers efforts to produce ATP competitive inhibitors that are highly selective to CK2 alpha 1. Hematein was identified previously as a non-ATP-competitive inhibitor for CK2 alpha 1, whereas this compound acts as an ATP competitive CK2 alpha 2 inhibitor. Crystal structures of CK2 alpha 1 and CK2 alpha 2 in complex with hematein revealed distinct binding features that provide structural insights for producing CK2 alpha 1-selective inhibitors.
引用
收藏
页数:4
相关论文
共 50 条
  • [21] Recent Advances in the Discovery of CK2 Inhibitors
    Al-Qadhi, Mustafa A.
    Yahya, Tawfeek A. A.
    El-Nassan, Hala B.
    ACS OMEGA, 2024, 9 (19): : 20702 - 20719
  • [22] Synthesis of benzoxazole inhibitors of kinase CK2
    Popa, Bogdan
    Schwegman, Eric
    Liyanage, Duminda
    Eagon, Scott
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2019, 258
  • [23] Expanding the chemical diversity of CK2 inhibitors
    Prudent, Renaud
    Moucadel, Virginie
    Lopez-Ramos, Miriam
    Aci, Samia
    Laudet, Beatrice
    Mouawad, Liliane
    Barette, Caroline
    Einhorn, Jacques
    Einhorn, Cathy
    Denis, Jean-Noel
    Bisson, Gilles
    Schmidt, Frederic
    Roy, Sylvaine
    Lafanechere, Laurence
    Florent, Jean-Claude
    Cochet, Claude
    MOLECULAR AND CELLULAR BIOCHEMISTRY, 2008, 316 (1-2) : 71 - 85
  • [24] An unbiased evaluation of CK2 inhibitors by chemoproteomics
    Duncan, James S.
    Gyenis, Laszlo
    Lenehan, John
    Bretner, Maria
    Graves, Lee M.
    Haystead, Timothy A.
    Litchfield, David W.
    MOLECULAR & CELLULAR PROTEOMICS, 2008, 7 (06) : 1077 - 1088
  • [25] Crystal structure of human protein kinase CK2: insights into basic properties of the CK2 holoenzyme
    Niefind, K
    Guerra, B
    Ermakowa, I
    Issinger, OG
    EMBO JOURNAL, 2001, 20 (19): : 5320 - 5331
  • [26] Protein kinase CK2: from structures to insights
    K. Niefind
    J. Raaf
    O.-G. Issinger
    Cellular and Molecular Life Sciences, 2009, 66 : 3535 - 3536
  • [27] In search of a new prototype in CK2 inhibitors design
    Maslyk, Maciej
    Zapico, Jose M.
    Swider, Robert
    Martin-Santamaria, Sonsoles
    Ramos, Ana
    de Pascual-Teresa, Beatriz
    ARKIVOC, 2011, : 54 - 71
  • [28] Tetraiodobenzimidazoles are potent inhibitors of protein kinase CK2
    Gianoncelli, Alessandra
    Cozza, Giorgio
    Orzeszko, Andrzej
    Meggio, Flavio
    Kazimierczuk, Zygmunt
    Pinna, Lorenzo A.
    BIOORGANIC & MEDICINAL CHEMISTRY, 2009, 17 (20) : 7281 - 7289
  • [29] The selectivity of inhibitors of protein kinase CK2: an update
    Pagano, Mario A.
    Bain, Jenny
    Kazimierczuk, Zygmunt
    Sarno, Stefania
    Ruzzene, Maria
    Di Maira, Giovanni
    Elliott, Matthew
    Orzeszko, Andrzej
    Cozza, Giorgio
    Meggio, Flavio
    Pinna, Lorenzo A.
    BIOCHEMICAL JOURNAL, 2008, 415 (353-365) : 353 - 365
  • [30] Protein kinase CK2 inhibitors: a patent review
    Cozza, Giorgio
    Pinna, Lorenzo A.
    Moro, Stefano
    EXPERT OPINION ON THERAPEUTIC PATENTS, 2012, 22 (09) : 1081 - 1097